DEPARTMENT of OBSTETRICS &

GYNECOLOGY
UPUMS

HEALTH BENEFITS, ADVERSE EFFECTS OF

COCs
& TRIPHASIC FORMULATIONS

MODERATED BY:
PRESENTED BY:
DR. SONIYA VISHWAKARMA MA’AM
JAI SHRI RAM
ROLL NO. 40
 CONTENT
Health benefits of COCs
Adverse effects of COCs
Triphasic formulations
 HEALTH BENEFITS OF COCs
CONTRACEPTIVE BENEFITS
 Protection against unwanted pregnancy
(FR=0.1/ 100 wy)
 Reversibility
 Convenient to use
 Not intercourse related
 Improving maternal and child health care
NON-CONTRACEPTIVE BENEFITS

IMPROVEMENT OF MENSTRUAL ABNORMALITIES

 Regulation of menstrual cycle
 Regulation of dysmenorrhea(40%)
 Reduction of menorrhagia(50%)
 Reduction of PMS
 Reduction of Mittelschmerz syndrome
 Protection against iron-deficiency anemia
 BENEFITS AGAINST HEALTH DISORDERS
• Increased bone density
• Reduced menstrual blood loss and anemia
• Decreased risk of ectopic pregnancy
• Improved dysmenorrhea from endometriosis
• Decreased risk of endometrial & ovarian cancer
• Reduction in various benign breast diseases
• Inhibition of hirsutism progression
• Acne improvement
• Prevention of atherogenesis
• Decreased incidence & severity of acute
salpingitis
• Decreased activity of rheumatoid arthritis
PREVENTION OF MALIGNANCIES
 Endometrial cancer (50%)
 Epithelial ovarian cancer (50%)
 Colorectal cancer (40%)
ADVERSE EFFECTS OF COCs
MINOR COMPLICATIONS
 Nausea , vomiting, headache & leg cramps
 Mastalgia
 Weight gain
 Chloasma and acne
 Libido
 Leukorrhea
 Menstrual abnormalities
MENSTRUAL ABNORMALITIES
• Breakthrough bleeding
• Hypomenorrhea
• Menorrhagia
• amenorrhea
MAJOR COMPLICATIONS (rare)
 Depression
 Hypertension
 Diabetes mellitus
 Vascular complications:
• venous thromboembolism
• arterial thrombosis
 Cholestatic jaundice
 Neoplasia
 Death: risk= 1.5/100,000
 TRIPHASIC FORMULATIONS

 In these preparations , the hormonal dose of

each compound vary over the course of cycle
 It is an attempt to minimize undesirable side
effect on lipid metabolism
 This is due to low total amount of steroids
and the balanced estrogen-progesterone
relationship
Triquilar tablets (Shering-AG)

 First 6 tablets contain 0.05mg

levonorgestrel and 30 mg of ethinyl
estradiol

 Next 5 tablets contain 0.075 mg

levonorgestrel and 40 mg ethinyl estradiol

 Last 10 tablets contains 0.125 mg

levonorgestrel and 30 mg ethinyl estradiol.